FDA found Green Pharmaceuticals' SnoreStop NasoSpray contaminated with Providencia rettgeri and sold as an unapproved new drug.
What happened
FDA laboratory testing of a batch of SnoreStop NasoSpray (lot 2373/21222) found gross microbial contamination, including Providencia rettgeri, with total aerobic counts from 420 to 6,200 CFU/mL and yeast/mold counts from 30 to 3,800 CFU/mL. After a June 2, 2022 teleconference and review of records, FDA determined the firm's manufacturing methods, facilities, or controls did not conform to CGMP; the firm said it did not test finished products for objectionable microorganisms before release and relied on its contract manufacturer's certificate of analysis. FDA also found the product label made it an unapproved new drug for snoring.
What FDA found
A sample of lot 2373/21222 had gross microbial contamination and was contaminated with Providencia rettgeri.
section 501(a)(1) of the FD&C Act, 21 U.S.C. 351(a)(1)FDA determined from the firm's records that its methods, facilities, or controls for manufacturing did not conform to CGMP.
section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)The firm released finished drug product without testing each batch for objectionable microorganisms and relied on the contract manufacturer's certificate of analysis.
21 CFR 211.165(b); section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)SnoreStop was marketed as a homeopathic anti-snoring drug without an FDA-approved application.
sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks the firm to correct the violations promptly and respond in writing within 15 working days with corrective actions and the requested microbiology, manufacturing, risk-assessment, investigation, specification, test-method, and retain-sample testing information. FDA also recommends engaging a qualified CGMP consultant.
Who should pay attention
- distributors and brands of OTC nasal sprays
- drug companies that rely on contract manufacturers for release testing
- quality teams handling microbial contamination and recalls
This is a summary. Read the original letter on fda.gov.